AnaptysBio (ANAB) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed AnaptysBio (ANAB) over the past year, gaining 335.5% versus a gain of 117.8%. Over five years, OMER leads with a +147.3% price change compared with +141.8% for ANAB. Omeros is the larger company by market cap ($1.38 billion vs $1.38 billion), about 1.0 times the size.
On valuation, AnaptysBio trades at a lower forward P/E (9.1x vs 15.5x for Omeros).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | OMER |
|---|---|---|
| Share price | $46.21 | $19.12 |
| Market cap | $1.38B | $1.38B |
| 1-day change | +1.23% | +1.97% |
| YTD return | +42.98% | +11.29% |
| 1-year return | +117.77% | +335.54% |
| 5-year return | +141.77% | +147.35% |
| P/E ratio (TTM) | — | 15.67 |
| Forward P/E | 9.12 | 15.54 |
| EPS (TTM) | $-0.96 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $21.24 |
| 52-week low | $20.18 | $4.06 |
| Distance from 52-week high | -36.14% | -9.98% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.81% | +43.83% |
| Average volume | 563.32K | 1.74M |
| Shares outstanding | 29.90M | 72.39M |
| Employees | — | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed ANAB by 217.8 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
ANAB vs OMER FAQ
Which is bigger, AnaptysBio or Omeros?
Omeros (OMER) is larger, with a market capitalization of $1.38B compared with $1.38B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or OMER?
OMER returned +335.54% over the past 12 months, compared with +117.77% for ANAB (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.